CULPRIT-SHOCK

Partner 16 - Golden Jubilee National Hospital

Keith Oldroyd

 Golden Jubilee National Hospital

Prof. Keith Oldroyd

Principal Investigator
Phone: +44 141 951 5000
E-mail

undefinedPubMed

undefinedResearchGate

 

Golden Jubilee National Hospital

Agamemnon Street, Clydebank

Clydebank

G81 4DY

Scotland

Website


CULPRIT-SHOCK Team Golden Jubilee National Hospital

Barry Hennigan

 

Dr. Barry Hennigan

Interventional/Research Fellow
Phone: +447460911711
E-mail

Joanne Kelly

Senior Interventional Cardiology Research Nurse
E-mail

Institute Presentation

The Golden Jubilee National Hospital is a national tertiary referral hospital for PCI and over 6000 invasive coronary procedures are performed annually as well as 800-900 primary PCI procedures. Our hospital has a busy cardiothoracic surgery service and undertakes approximately 1,400 major heart operations every year including cardiac transplantation. The Golden Jubilee National Hospital has 300 beds overall with all wards having single or two bedded rooms with ensuite facilities. With this array of specialist cardiopulmonary services for a catchment population of 2.2 million, the GJNH is one of the largest heart and lung centres in Europe.There are two intensive care units with a total of 22 physical beds and there are 16 high dependency beds in two separate units. In addition to providing care to cardiac surgical patients, the critical care unit also manages patients critically ill with heart failure and patients undergoing heart transplant and mechanical circulatory support under the Scottish National Advanced Heart Failure Service and it supports the regional primary angioplasty service. The Heart and Lung Centre also benefits from MRI and CT imaging facilities with capabilities for CT angiography and a brand new 64 slice CT.

 

Our experience in clinical research to date is exemplary. We were recently involved in the PRAMI trial which involved recruitment of patIents with multi vessel disease and STEMI with subsequent PCI to culprit only or multi vessel PCI to all vessels with >50% angiographic stenosis. This trial showed a net clinical benefit of multi vessel PCI in a particular subgroup of multi vessel disease patients and is among one of the most clinically important cardiology trials in recent years. Our execution of the trial protocol ,despite the clinical demands, with our rapid recruitment stand testament to our dedication and ability to execute a trial protocol like CULPRIT SHOCK in a timely and efficient manner.

Our experience in coronary physiology research is exemplified by our many previous journal publications including the recently published VERIFY study 2013, co-authorship in FAME and FAME 2 as well as our notable paper in 2012 which showed that microvascular resistance measured during primary percutaneous coronary intervention significantly predicts myocardial salvage and left ventricular ejection fraction in patients with ST-elevation myocardial infarction. We have also received hands on training in the use of both the Volcano Combowire and the Cytocam system in order to prepare for our participation in the Microcirculation sub study of CULPRIT SHOCK.

 

Our four clinical research nurse specialists ,lead by Ms. Joanne Kelly, are highly experienced in recruitment and followup of clinical trial patients and are currently working on many large international studies including GLOBAL LEADERS, LEADERS FREE, NOBLE, REVIVED as well as our institutional research studies.

CULPRIT-SHOCK Consortium

The CULPRIT-SHOCK Consortium consists of 17 partners from 11 different EU member states as well as Switzerland.

CULPRIT-SHOCK Workpackages

CULPRIT-SHOCK Workpackages

Home
Menu
Search
Top

Newsletter Subscription